Picture this: hitting the ripe old age of 85 and discovering that your risk of developing cancer might actually start to drop – a mind-blowing revelation from a groundbreaking Stanford University study that flips everything we thought we knew about ageing and cancer on its head!
But here's where it gets controversial... New findings from Stanford (accessible via https://news.stanford.edu/stories/2025/11/extreme-advanced-age-cancer-risk-older-people-research-study) suggest that extreme old age could unleash unexpected protective powers against cancer. Through experiments on genetically modified mice, researchers found that very elderly rodents formed fewer and less sizeable tumors than their younger counterparts. This directly clashes with the long-held idea that cancer risk just keeps climbing as we get older.
These results point to the possibility that the ageing process itself might activate natural defenses that curb tumor growth – a pattern that echoes observations in extremely elderly humans, where cancer rates seem to level off or even decrease around age 85. And this is the part most people miss... It could reshape how we approach cancer research and tailor treatments for seniors. By unlocking the secrets of how ageing shifts our vulnerability to cancer, we might one day create therapies that tap into these built-in safeguards.
Diving deeper, the study showed how ageing curbs tumor growth in older mice. Scientists pitted lung cancer development in young mice (around four to six months old) against that in old ones (about 20 to 21 months). The young group sprouted numerous large tumors, while the seniors had far fewer, and those were much tinier. This hints that ageing's natural progression could be holding back cancer, offering a fresh lens on why cancer rates might stabilize or dip in people over 85.
Monte Winslow, PhD, an associate professor of genetics and pathology at Stanford, was taken aback by these outcomes. 'We'd typically predict that older animals would face worse and more cancers, but our data showed the opposite,' he noted. 'The real puzzle now is figuring out how ageing's molecular shifts might actually dampen cancer growth.'
Of course, exploring the ties between age and cancer isn't straightforward. Most lab work has relied on young animals, making it tough to spot these age-related twists. Emily Shuldiner, PhD, who led the study, explained that when they triggered the same cancer-causing genetic changes in both young and old mice, the differences were stark. Young mice saw swift tumor expansion, whereas older ones experienced slower growth and smaller sizes. Published in Nature Aging, the research stresses why age must be a key player in cancer studies – without it, we risk missing how treatments might play out differently in older individuals.
Now, why does cancer risk seem to flatline in the very elderly? We know cancer risk generally surges with age because DNA errors build up as cells divide. It often spikes dramatically from about 50 years old, peaking between 70 and 80. Yet, past 85, data indicates it may stabilize or even fall. Experts have pondered if this is due to less frequent screenings, a bias toward survivors, or stronger immune systems in those who reach such advanced ages. But here's where it gets controversial again... The mouse study proposes something more intrinsic: ageing might trigger built-in biological brakes on tumor formation. Dmitri Petrov, PhD, a professor of biology, put it bluntly: 'Beyond a certain age, ageing itself seems to switch into a cancer-suppressing mode.'
Let's break this down for beginners: Ageing impacts our cells in various ways, like altering DNA methylation (a process that controls gene activity), stabilizing the genome, and tweaking chromosome setups. Surprisingly, some of these shifts may actually block cancer's progress. Shuldiner's team saw that even in fast-multiplying cancer cells, older mice retained clear markers of ageing. They also tested disabling 25 genes that usually fight cancer – tumor growth ramped up in both groups, but the effect was far stronger in the young mice. One standout was the PTEN gene, a crucial tumor suppressor, which behaved differently with age. This could mean therapies targeting genes like this might need adjustments for younger versus older patients – imagine customizing cancer drugs based on age, like tailoring a suit to fit perfectly.
These discoveries call for a rethink in cancer research and care. Models that only use young animals could ignore vital ageing factors affecting how tumors form and respond to treatment. Winslow emphasized the real-world impact: 'To make animal studies truly useful for human therapies, we need to factor in ageing – otherwise, we overlook unique traits in older patients.' Petrov added, 'This opens the door to exploiting ageing's upsides for better cancer treatments in seniors.' And this is the part most people miss... Could we one day harness ageing's protective side as a tool against cancer, rather than just fighting it?
Shifting to prevention on a broader scale, the World Health Organization estimates that 30 to 50 percent of cancers could be avoided. Key culprits include lifestyle choices like smoking and heavy drinking, infections such as hepatitis and HPV, unhealthy eating, weight gain, and exposures to pollution or radiation. Public health efforts focus on cutting these risks – for instance, campaigns promoting quitting smoking or vaccinations against cancer-causing viruses. Yet, the Stanford insights suggest we might blend these with biological strategies inspired by ageing to shield our growing senior population from cancer. For more on related health topics, check out this piece on Type 1 vs. Type 2 Diabetes: Which is riskier and how to prevent serious complications (https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/type-1-vs-type-2-diabetes-which-is-riskier-and-how-to-prevent-serious-complications/articleshow/125295140.cms).
What do you think? Is it time to view ageing not just as a foe but as a potential ally in the cancer battle? Could this shift in perspective lead to groundbreaking treatments, or does it downplay the need for aggressive prevention? Share your thoughts in the comments – do you agree with embracing ageing's protective mechanisms, or do you see this as a controversial oversimplification? We'd love to hear your take!
